This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
JHEP reports : innovation in hepatology, 7(11), 101483
Citation
Browne, Sarah K; Suschak, John J; Tomah, Shaheen; Gutierrez, Julio A; Yang, Jay; Georges, Bertrand; Roberts, M Scot; Harris, M Scott. (2025). Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.. JHEP reports : innovation in hepatology, 7(11), 101483. https://doi.org/10.1016/j.jhepr.2025.101483